Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3085% below fair value
$16.07+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $1.70BP/E –Yield –
Sarepta Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Sarepta Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -5.9%. For fiscal 2025 it was -32.5%, against 12.4% the year before. The highest annual figure on record is 12.4% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -32.5% | −44.8 |
| FY2024 | Dec 31, 2024 | 12.4% | +55.5 |
| FY2023 | Dec 31, 2023 | -43.1% | +32.3 |
| FY2022 | Dec 31, 2022 | -75.4% | −15.7 |
| FY2021 | Dec 31, 2021 | -59.7% | +42.9 |
| FY2020 | Dec 31, 2020 | -102.6% | +85.2 |
| FY2019 | Dec 31, 2019 | -187.8% | −67.5 |
| FY2018 | Dec 31, 2018 | -120.2% | −87.4 |
| FY2017 | Dec 31, 2017 | -32.8% | +4897.4 |
| FY2016 | Dec 31, 2016 | -4930.2% | +12630.1 |
| FY2015 | Dec 31, 2015 | -17560.3% | −16168.5 |
| FY2014 | Dec 31, 2014 | -1391.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -7.5% | +5.2 |
| Q2 FY2026 | Jun 30, 2026 | -1.2% | −33.4 |
| Q1 FY2026 | Mar 31, 2026 | 45.3% | +105.4 |
| Q4 FY2025 | Dec 31, 2025 | -93.1% | −117.2 |
| Q3 FY2025 | Sep 30, 2025 | -12.7% | −19.9 |
| Q2 FY2025 | Jun 30, 2025 | 32.2% | +30.4 |
| Q1 FY2025 | Mar 31, 2025 | -60.1% | −68.8 |
| Q4 FY2024 | Dec 31, 2024 | 24.2% | +12.7 |
| Q3 FY2024 | Sep 30, 2024 | 7.2% | +19.5 |
| Q2 FY2024 | Jun 30, 2024 | 1.8% | +10.9 |
| Q1 FY2024 | Mar 31, 2024 | 8.7% | +212.6 |
| Q4 FY2023 | Dec 31, 2023 | 11.5% | +53.8 |
| Q3 FY2023 | Sep 30, 2023 | -12.3% | +99.6 |
| Q2 FY2023 | Jun 30, 2023 | -9.2% | +90.0 |
| Q1 FY2023 | Mar 31, 2023 | -203.8% | −154.0 |
| Q4 FY2022 | Dec 31, 2022 | -42.3% | +18.3 |
| Q3 FY2022 | Sep 30, 2022 | -111.9% | −86.5 |
| Q2 FY2022 | Jun 30, 2022 | -99.1% | −49.5 |
| Q1 FY2022 | Mar 31, 2022 | -49.8% | +64.0 |
| Q4 FY2021 | Dec 31, 2021 | -60.5% | +69.9 |
| Q3 FY2021 | Sep 30, 2021 | -25.4% | +111.1 |
| Q2 FY2021 | Jun 30, 2021 | -49.6% | +60.2 |
| Q1 FY2021 | Mar 31, 2021 | -113.8% | −98.4 |
| Q4 FY2020 | Dec 31, 2020 | -130.4% | +105.0 |
| Q3 FY2020 | Sep 30, 2020 | -136.5% | −9.0 |
| Q2 FY2020 | Jun 30, 2020 | -109.8% | +182.2 |
| Q1 FY2020 | Mar 31, 2020 | -15.4% | +72.7 |
| Q4 FY2019 | Dec 31, 2019 | -235.4% | −68.5 |
| Q3 FY2019 | Sep 30, 2019 | -127.5% | −30.2 |
| Q2 FY2019 | Jun 30, 2019 | -292.0% | −143.4 |
| Q1 FY2019 | Mar 31, 2019 | -88.1% | −33.3 |
| Q4 FY2018 | Dec 31, 2018 | -166.9% | −125.0 |
| Q3 FY2018 | Sep 30, 2018 | -97.3% | +6.5 |
| Q2 FY2018 | Jun 30, 2018 | -148.6% | +31.5 |
| Q1 FY2018 | Mar 31, 2018 | -54.7% | −569.3 |
| Q4 FY2017 | Dec 31, 2017 | -41.9% | +1589.8 |
| Q3 FY2017 | Sep 30, 2017 | -103.9% | – |
| Q2 FY2017 | Jun 30, 2017 | -180.1% | – |
| Q1 FY2017 | Mar 31, 2017 | 514.6% | – |
| Q4 FY2016 | Dec 31, 2016 | -1631.7% | – |
See a number that looks wrong?